N-Acetyl Semax (25mg) Research Peptide

Product Introduction

N-Acetyl Semax (25mg) is a research-grade peptide supplied by Core Peptides for laboratory and scientific research applications. Each vial contains 25mg of N-Acetyl Semax, providing researchers with a defined peptide material for controlled experimental studies.

N-Acetyl Semax is a modified form of the peptide Semax that has been investigated in scientific research involving peptide signaling, molecular pathways, and cellular processes. The N-acetyl modification is of particular interest in peptide research because chemical modifications can influence the properties and behavior of peptide molecules in experimental systems.

N-Acetyl Semax (25mg) is supplied with an emphasis on quality, consistency, and reliable laboratory use. It is intended exclusively for scientific research and is not intended for human or veterinary use.

What Is N-Acetyl Semax?

N-Acetyl Semax is a chemically modified peptide related to Semax. Semax itself is a synthetic peptide sequence that has been the subject of scientific investigation, while N-acetylation represents a structural modification that researchers can examine when studying peptide characteristics and biological interactions.

Modified peptides are useful research tools because relatively small changes to a peptide structure can influence its molecular properties, stability, interactions, and behavior under experimental conditions.

Researchers studying N-Acetyl Semax can therefore investigate how the modified peptide behaves in controlled laboratory environments and compare its characteristics with other peptide materials.

N-Acetyl Semax Research Applications

N-Acetyl Semax may be relevant to research involving peptide chemistry, molecular biology, cellular signaling, and biochemical research. Experimental studies can investigate peptide-receptor interactions, molecular pathways, peptide stability, and other mechanisms of interest.

The specific research application depends on the experimental model and objectives of the laboratory. Researchers may use appropriate biochemical or analytical methods to characterize the peptide and investigate its behavior under controlled conditions.

The concentration, experimental methodology, controls, and handling procedures should be determined by qualified researchers according to their established laboratory protocols.

Product Specifications

Quality and Consistency

Consistent research materials are essential when conducting controlled laboratory studies. N-Acetyl Semax (25mg) is supplied with an emphasis on quality, consistency, and suitability for scientific research.

Researchers should review available product and batch documentation when evaluating N-Acetyl Semax for a particular experimental application. Appropriate analytical methods and controls should be used when assessing the material within a research system.

Packaging and Handling

Each N-Acetyl Semax (25mg) product is securely packaged to help protect the research material during storage and transportation.

Researchers should follow the applicable product documentation and their laboratory’s established procedures for storage, handling, and preparation. Appropriate laboratory safety practices should always be followed when working with research peptides.

Why Choose Core Peptides?

Core Peptides provides research-focused peptide materials for laboratories, researchers, and scientific investigations. N-Acetyl Semax (25mg) provides researchers with a defined quantity of modified Semax peptide for controlled experimental work.

Clear product identification, quantity information, research-use positioning, and secure packaging help researchers evaluate the material for their specific laboratory requirements.

Research Use Disclaimer

N-Acetyl Semax (25mg) is supplied strictly for laboratory and scientific research purposes. It is not approved or intended for human consumption, self-administration, diagnosis, treatment, prevention, or mitigation of any disease or medical condition. It is not intended for veterinary use. Researchers are responsible for complying with applicable laws, institutional requirements, laboratory safety standards, and appropriate handling procedures.

Product Features

• Contains 25mg of N-Acetyl Semax
• Modified synthetic peptide
• Research-grade laboratory material
• Suitable for peptide and molecular research
• Relevant to biochemical and cellular research
• Quality-focused production
• Securely packaged
• For research use only
• Not for human or veterinary use

References

1. Asmarin IP, Nezavibat’ko VN, Miasoedov NF, Kamenskiĭ AA, Grivennikov IA, Ponomareva-Stepnaia MA, Andreeva LA, Kaplan AIa, Koshelev VB, Riasina TV. Nootropnyĭ analog adrenokortikotropina 4-10-semaks (15-letniĭ opyt razrabotki i izucheniia) [A nootropic adrenocorticotropin analog 4-10-semax (l5 years experience in its design and study)]. Zh Vyssh Nerv Deiat Im I P Pavlova. 1997 Mar-Apr;47(2):420-30. Russian. PMID: 9173745. https://pubmed.ncbi.nlm.nih.gov/9173745/
2. Nataliya Yu. Glazova, Daria M. Manchenko, Maria A. Volodina, Svetlana A. Merchieva, Ludmila A. Andreeva, Vladimir S. Kudrin, Nikolai F. Myasoedov, Natalia G. Levitskaya, Semax, synthetic ACTH(4–10) analog, attenuates behavioural and neurochemical alterations following early-life fluvoxamine exposure in white rats, Neuropeptides, Volume 86, 2021, 102114, ISSN 0143-4179. https://doi.org/10.1016/j.npep.2020.102114
3. Volodina MA, Sebentsova EA, Glazova NY, Levitskaya NG, Andreeva LA, Manchenko DM, Kamensky AA, Myasoedov NF. Semax attenuates the influence of neonatal maternal deprivation on the behavior of adolescent white rats. Bull Exp Biol Med. 2012 Mar;152(5):560-3. English, Russian. doi: 10.1007/s10517-012-1574-2. PMID: 22803132. https://pubmed.ncbi.nlm.nih.gov/22803132/
4. Gavrilova SA, Golubeva AV, Lipina TV, Fominykh ES, Shornikova MV, Postnikov AB, Andrejeva LA, Chentsov IuS, Koshelev VB. [Protective effect of peptide semax (ACTH(4-7)Pro-Gly-Pro) on the rat heart rate after myocardial infarction]. Ross Fiziol Zh Im I M Sechenova. 2006 Nov;92(11):1305-21. Russian. PMID: 17385423. https://pubmed.ncbi.nlm.nih.gov/17385423/
5. Gusev EI, Skvortsova VI, Miasoedov NF, Nezavibat’ko VN, Zhuravleva EIu, Vanichkin AV. Effektivnost’ semaksa v ostrom periode polusharnogo ishemicheskogo insul’ta (klinicheskoe i élektrofiziologicheskoe issledovanie) [Effectiveness of semax in acute period of hemispheric ischemic stroke (a clinical and electrophysiological study)]. Zh Nevrol Psikhiatr Im S S Korsakova. 1997;97(6):26-34. Russian. PMID: 11517472. https://pubmed.ncbi.nlm.nih.gov/11517472/